Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Trial Comparing the Efficacy and Safety of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily With Tiotropium 18 mcg Once Daily Over 24 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: The purpose of this 24 week study is to evaluate the spirometric lung function effect (trough FEV1) of Umeclidinium/Vilanterol 62.5/25 once daily compared to Tiotropium 18 mcg once daily along with safety assessments in subjects with COPD.


Options:
A: Arm Label: Indacaterol 150 μg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 150 µg | Arm Label: Indacaterol 300 μg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 300 μg | Arm Label: Placebo to indacaterol; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to indacaterol | Intervention Type: DRUG; Name: Indacaterol 150 µg; Assigned to Arm(s): Indacaterol 150 μg | Intervention Type: DRUG; Name: Indacaterol 300 μg; Assigned to Arm(s): Indacaterol 300 μg | Intervention Type: DRUG; Name: Placebo to indacaterol; Assigned to Arm(s): Placebo to indacaterol
B: Arm Label: QVA149 + placebo to tiotropium; Type: EXPERIMENTAL; Interventions: Drug: QVA149, Drug: Placebo to tiotropium, Drug: Salbutamol/albuterol | Arm Label: Tiotropium + placebo to QVA149; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium, Drug: Placebo to QVA149, Drug: Salbutamol/albuterol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to QVA149, Drug: Placebo to tiotropium, Drug: Salbutamol/albuterol | Intervention Type: DRUG; Name: QVA149; Assigned to Arm(s): QVA149 + placebo to tiotropium | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Tiotropium + placebo to QVA149 | Intervention Type: DRUG; Name: Placebo to QVA149; Assigned to Arm(s): Placebo, Tiotropium + placebo to QVA149 | Intervention Type: DRUG; Name: Placebo to tiotropium; Assigned to Arm(s): Placebo, QVA149 + placebo to tiotropium | Intervention Type: DRUG; Name: Salbutamol/albuterol; Assigned to Arm(s): Placebo, QVA149 + placebo to tiotropium, Tiotropium + placebo to QVA149
C: Arm Label: Umeclidinium/Vilanterol; Type: EXPERIMENTAL; Interventions: Drug: Umeclidinium/Vilanterol 62.5/25 mcg | Arm Label: Tiotropium; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium 18 mcg | Intervention Type: DRUG; Name: Umeclidinium/Vilanterol 62.5/25 mcg; Assigned to Arm(s): Umeclidinium/Vilanterol | Intervention Type: DRUG; Name: Tiotropium 18 mcg; Assigned to Arm(s): Tiotropium
D: Arm Label: QVA149; Type: EXPERIMENTAL; Interventions: Drug: indacaterol and glycopyrronium (QVA149), Drug: Placebo to fluticasone/salmeterol | Arm Label: fluticasone/salmeterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluticasone/salmeterol, Drug: Placebo to indacaterol and glycopyrronium (QVA149) | Intervention Type: DRUG; Name: indacaterol and glycopyrronium (QVA149); Assigned to Arm(s): QVA149 | Intervention Type: DRUG; Name: Placebo to fluticasone/salmeterol; Assigned to Arm(s): QVA149 | Intervention Type: DRUG; Name: fluticasone/salmeterol; Assigned to Arm(s): fluticasone/salmeterol | Intervention Type: DRUG; Name: Placebo to indacaterol and glycopyrronium (QVA149); Assigned to Arm(s): fluticasone/salmeterol

Answer: C